Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 12.56B |
| Revenue (ttm) | 4.27B |
| Net Income (ttm) | -356.15M |
| Shares Out | 61.56M |
| EPS (ttm) | -5.84 |
| PE Ratio | n/a |
| Forward PE | 8.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 591,081 |
| Open | 202.19 |
| Previous Close | 201.22 |
| Day's Range | 200.30 - 204.28 |
| 52-Week Range | 97.50 - 207.48 |
| Beta | 0.23 |
| Analysts | Strong Buy |
| Price Target | 217.57 (+6.66%) |
| Earnings Date | May 5, 2026 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price target is $217.57, which is an increase of 6.66% from the latest price.
News
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced tha...
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U...
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and real-world treatment patterns in...
Jazz Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
Record revenue growth continues, with a sharpened focus on rare diseases and robust business development. Key pipeline assets like zanidatamab and Modeyso are advancing, while XYWAV and Epidiolex sustain strong performance. Multiple regulatory and clinical milestones are expected this year.
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
Six abstracts, including one oral presentation, underscore Jazz's ongoing commitment to generating real-world evidence addressing rare neurological disorders, including rare and severe forms of epilep...
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
DUBLIN, April 1, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25th Annual Needham Healthcare Conference. Company management wil...
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education
Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness CHICAGO, March 24, 2026 /PRNewswire/...
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditi...
Jazz Pharmaceuticals (JAZZ) Price Forecast: Multi-Year Base Signals Breakout Potential
Shares of Jazz Pharmaceuticals plc are consolidating below record highs after a bull-flag breakout, with tightening price action suggesting a potential breakout from a multi-year base.
Jazz Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Record 2025 revenue was driven by strong growth in Xywav, Epidiolex, and Modeyso, with continued expansion in oncology and epilepsy. Zanidatamab is advancing rapidly, and strategic investments are focused on rare diseases and pipeline growth. Robust financial resources support ongoing corporate development.
Jazz Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Record 2025 revenue and strong growth in epilepsy and oncology set the stage for 2026, with key pipeline advances in zanidatamab and Modeyso. Strategic acquisitions, expanded exclusivity, and a focus on rare diseases drive momentum, supported by robust financial guidance.
Jazz Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 revenue of $4.3B was driven by strong growth in rare disease and oncology, with new launches and portfolio expansion. 2026 guidance anticipates continued growth in oncology and epilepsy, offset by sleep franchise headwinds from generics.
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 – – Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA – – Xywav® achie...
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, Feb. 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences: TD Cowen 46th Annual Health Care ...
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the c...
Jazz Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Record revenues, key product launches, and practice-changing clinical data marked a strong year, with a sharpened focus on rare diseases and robust R&D pipeline. Zanidatamab is poised to become a new standard in HER2-positive GEA, and commercial momentum remains strong despite generic competition.
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic cl...
Jazz Pharmaceuticals Transcript: Study result
Phase III data show zanidatamab plus chemotherapy, with or without tislelizumab, significantly improves survival outcomes over trastuzumab in first-line HER2-positive GEA, with benefits seen across all PD-L1 subgroups. Regulatory submission and rapid adoption are anticipated.
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ --...
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Positive Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard...
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
DUBLIN , Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 Investor W...
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, in...
Trials, Sales Wins Sends Jazz Pharmaceuticals Higher
Jazz Pharmaceuticals PLC (JAZZ) shares up 352% since Big Money bought big in 2015.
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to ...
Jazz Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025
Record Q3 revenues were driven by strong growth in key brands, with guidance raised and a robust cash position supporting ongoing business development. Oncology and epilepsy remain strategic priorities, with new launches and pipeline advances fueling future growth.